www.fdanews.com/articles/149543-jennerex-phase-ii-trial-of-jx594-meets-key-clinical-endpoints

Jennerex Phase II Trial of JX594 Meets Key Clinical Endpoints

September 18, 2012

Jennerex has announced positive clinical data from Phase II trial of JX594, a proprietary, engineered oncolytic immunotherapy, in sorafenib-refractory hepatocellular carcinoma (liver cancer, HCC) patients.
Pharmaceutical Business Review